Flutamide administration at 500 mg dialy has similar effects on serum testosterone to 750 mg daily

Journal of Andrology

Volumn 25, Issue 4, 2004, Pages 630-634

  Murphy, Jeremiah C ^a   Srinivas, Sandy ^b   Terris, Martha K ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Androgen deprivation; Antiandrogen; Hormone; Prostate neoplasm; PSA

Indexed keywords

FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERECTILE DYSFUNCTION; FATIGUE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LIBIDO DISORDER; MALE; MASTALGIA; MOOD DISORDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

EID: 3042736735     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2004.tb02834.x     Document Type: Article

References (20)

1. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int. 2003;91:455-461.
2. Belanger A, Giasson M, Couture J, Dupont A, Cusan L, Labrie F. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate. 1988;12:79-84.
3. Boccon-Gibod L. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur Urol. 1998;33:159-164.
4. Cheston F. Use this new personal dosage record to promote patient compliance. Pharm Times. 1978;44:42-45.
5. Cornelis WA. Patient compliance aids. Drug Intell Clin Pharm. 1976;10: 541.
6. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6:592-599.
7. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int. 2001;87:47-56.
8. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years follow-up. J Urol. 2000;164:1579-1582.
9. Kolvenbag GJ, Iversen P, Newling DW. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology. 2001;58:16-23.
10. Luo S, Martel C, Chen C, Labrie C, Candas B, Singh SM, Labrie F. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology. 1997;50:913-919.
11. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist. 1997;2:18-27.
12. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239-1242.
13. Neri R. Pharmacology and pharmacokinetics of flutamide. Urology. 1989; 34:19-21.
14. Radwanski E, Perentesis G, Symchowicz S, Zampaglione N. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol. 1989;29:554-558.
15. Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol. 1988;34:633-636.
16. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 2000;7: 211-247.
17. Teutsch G, Goubet F, Battmann T, et al. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol. 1994;48:111-119.
18. Thrasher JB, Deeths J, Bennett C, lyer P, Dineen MK, Zhai S, Figg WD, McLeod DG. Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000;4:259-263.
19. Wakeling AE, Furr BJ, Glen AT, Hughes LR. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens. J Steroid Biochem. 1981;15:355-359.
20. Yagoda A. Flutamide-induced diarrhea secondary to lactose intolerance. J Natl Cancer Inst. 1989;81:1839-1840.